Modera Wealth Management LLC Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Modera Wealth Management LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,562 shares of the company’s stock, valued at approximately $231,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Knuff & Co LLC increased its position in shares of Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after acquiring an additional 244 shares during the last quarter. Stephens Inc. AR increased its position in shares of Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after purchasing an additional 245 shares during the last quarter. Allworth Financial LP raised its stake in shares of Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. raised its stake in shares of Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares in the last quarter. Finally, Larson Financial Group LLC grew its stake in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on MRNA. Barclays lowered shares of Moderna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. JPMorgan Chase & Co. set a $45.00 target price on Moderna in a report on Friday, February 14th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, Morgan Stanley decreased their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $60.63.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $35.21 on Thursday. The stock has a market capitalization of $13.58 billion, a P/E ratio of -3.79 and a beta of 1.86. The stock’s fifty day moving average is $36.82 and its 200 day moving average is $49.78. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.